ZA201704383B - Parg inhibitory compounds - Google Patents
Parg inhibitory compoundsInfo
- Publication number
- ZA201704383B ZA201704383B ZA2017/04383A ZA201704383A ZA201704383B ZA 201704383 B ZA201704383 B ZA 201704383B ZA 2017/04383 A ZA2017/04383 A ZA 2017/04383A ZA 201704383 A ZA201704383 A ZA 201704383A ZA 201704383 B ZA201704383 B ZA 201704383B
- Authority
- ZA
- South Africa
- Prior art keywords
- inhibitory compounds
- parg inhibitory
- parg
- compounds
- inhibitory
- Prior art date
Links
- 101150003479 Parg gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422771 | 2014-12-19 | ||
| PCT/GB2015/054064 WO2016097749A1 (en) | 2014-12-19 | 2015-12-17 | Parg inhibitory compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201704383B true ZA201704383B (en) | 2022-03-30 |
Family
ID=54937310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/04383A ZA201704383B (en) | 2014-12-19 | 2017-06-28 | Parg inhibitory compounds |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10508086B2 (https=) |
| EP (2) | EP3233845B1 (https=) |
| JP (1) | JP6673920B2 (https=) |
| KR (1) | KR102682782B1 (https=) |
| CN (2) | CN112979631B (https=) |
| AU (1) | AU2015365602B2 (https=) |
| BR (1) | BR112017012707B1 (https=) |
| CA (1) | CA2969298C (https=) |
| ES (1) | ES2886471T3 (https=) |
| IL (1) | IL252745B (https=) |
| MA (1) | MA41179A (https=) |
| MX (1) | MX380901B (https=) |
| RU (1) | RU2017125520A (https=) |
| SG (1) | SG11201704843QA (https=) |
| WO (1) | WO2016097749A1 (https=) |
| ZA (1) | ZA201704383B (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41140A (fr) | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| WO2020205646A2 (en) * | 2019-03-29 | 2020-10-08 | Board Of Regents, The University Of Texas System | Small molecule parg inhibitors and methods of use thereof |
| KR20220066922A (ko) * | 2019-09-20 | 2022-05-24 | 아이디어야 바이오사이언시스 인코포레이티드 | Parg 억제제로서 4-치환된 인돌 및 인다졸 설폰아미도 유도체 |
| US20250002491A1 (en) | 2021-10-04 | 2025-01-02 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| AU2022359801A1 (en) | 2021-10-04 | 2024-02-01 | Forx Therapeutics Ag | Parg inhibitory compounds |
| EP4401721A4 (en) | 2021-10-17 | 2025-10-15 | Univ Of South Alabama Foundation For Research And Commercialization | CANCER TREATMENT |
| AR128499A1 (es) * | 2022-02-14 | 2024-05-15 | Arase Therapeutics Inc | Inhibidores de parg |
| WO2023165571A1 (zh) * | 2022-03-04 | 2023-09-07 | 上海璎黎药业有限公司 | 一种含五元杂芳环结构化合物、其药物组合物及应用 |
| WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| AR128846A1 (es) | 2022-03-23 | 2024-06-19 | Ideaya Biosciences Inc | Compuestos de indazol sustituidos con piperazina como inhibidores de parg |
| CN114685283B (zh) * | 2022-04-06 | 2024-02-27 | 南京艾康生物科技有限公司 | 一种1-(氟甲基)环丙胺盐酸盐的制备方法 |
| WO2023205914A1 (en) * | 2022-04-28 | 2023-11-02 | Danatlas Pharmaceuticals Co., Ltd. | Tricyclic heterocyclic derivatives, compositions and uses thereof |
| CN118834213A (zh) * | 2022-04-28 | 2024-10-25 | 北京丹擎医药科技有限公司 | 三环杂环衍生物及其组合物和应用 |
| CA3251429A1 (en) | 2022-05-17 | 2023-11-23 | 858 Therapeutics, Inc. | PARG INHIBITORS |
| TWI878939B (zh) * | 2022-06-29 | 2025-04-01 | 大陸商杭州聖域生物醫藥科技有限公司 | 五元並六元含氮化物、其中間體、製備方法和應用 |
| AU2023310489A1 (en) * | 2022-07-19 | 2025-02-13 | Evopoint Biosciences Co., Ltd. | Sulfur-containing heteroaromatic ring compound, pharmaceutical composition thereof, and use thereof |
| EP4311829A1 (en) | 2022-07-28 | 2024-01-31 | Nodus Oncology Limited | Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer |
| JP2025535036A (ja) | 2022-10-03 | 2025-10-22 | フォークス セラピューティクス アーゲー | Ｐａｒｇ阻害化合物 |
| KR20240051861A (ko) * | 2022-10-13 | 2024-04-22 | 한미약품 주식회사 | Yap-tead 상호작용 억제를 위한 신규한 헤테로비시클릭 화합물 및 이를 포함하는 약학적 조성물 |
| WO2024120519A1 (zh) * | 2022-12-09 | 2024-06-13 | 捷思英达控股有限公司 | Tead抑制剂、其制备方法和在医学上的应用 |
| WO2024173234A1 (en) * | 2023-02-13 | 2024-08-22 | Arase Therapeutics Inc. | Inhibitors of parg |
| WO2024209035A1 (en) | 2023-04-05 | 2024-10-10 | Forx Therapeutics Ag | Parg inhibitory compounds |
| TWI908044B (zh) * | 2023-04-27 | 2025-12-11 | 大陸商北京丹擎醫藥科技有限公司 | 三環雜環衍生物及其組合物及其用途 |
| CN121548418A (zh) * | 2023-05-23 | 2026-02-17 | 康特克斯生物科技美国公司 | 二环杂芳基化合物 |
| CN119143747A (zh) * | 2023-06-16 | 2024-12-17 | 上海璎黎药业有限公司 | 一种杂芳环结构化合物、其药物组合物及应用 |
| WO2025035108A2 (en) * | 2023-08-10 | 2025-02-13 | Arase Therapeutics Inc. | Inhibitors of parg |
| WO2025046148A1 (en) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Novel parg inhibitors |
| CN121925410A (zh) | 2023-09-29 | 2026-04-24 | 第一三共株式会社 | 3-苯基丙胺衍生物 |
| CN121889393A (zh) | 2023-10-03 | 2026-04-17 | 福克斯治疗股份公司 | Parg抑制化合物 |
| WO2025093755A1 (en) | 2023-11-01 | 2025-05-08 | Forx Therapeutics Ag | Novel parc inhibitors |
| WO2025098445A1 (zh) * | 2023-11-07 | 2025-05-15 | 南京同诺康医药科技有限公司 | Parg抑制剂及其制备方法和用途 |
| WO2025108225A1 (zh) * | 2023-11-20 | 2025-05-30 | 上海复星医药（集团）股份有限公司 | 作为parg抑制剂的含氮三环衍生物 |
| WO2025133396A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Novel bicyclo heteroaryl parg inhibitors |
| WO2025229549A1 (en) * | 2024-04-30 | 2025-11-06 | Satyarx Pharma Innovations Pvt Ltd | Novel heterocyclic compounds as inhibitors of parg |
| WO2026022150A1 (en) | 2024-07-22 | 2026-01-29 | Forx Therapeutics Ag | Parg inhibitory compounds |
| WO2026040953A1 (zh) * | 2024-08-19 | 2026-02-26 | 上海和誉生物医药科技有限公司 | 一种多环parg抑制剂和其应用 |
| WO2026062066A1 (en) | 2024-09-17 | 2026-03-26 | Forx Therapeutics Ag | Compounds inducing parg degradation |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1157858A (en) | 1979-12-03 | 1983-11-29 | Ikuo Ueda | Quinazoline derivatives |
| DE4407047A1 (de) | 1994-03-03 | 1995-09-07 | Merck Patent Gmbh | Acetamide |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| US6291455B1 (en) | 1996-03-05 | 2001-09-18 | Zeneca Limited | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| EP1131856A1 (en) | 1998-11-12 | 2001-09-12 | BAE Systems Electronics Ltd. | Scanning of electromagnetic beams |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| SK288365B6 (sk) | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
| DE19927415A1 (de) | 1999-06-16 | 2000-12-21 | Bayer Ag | Indolinylharnstoffderivate |
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| NZ522074A (en) | 2000-05-31 | 2004-06-25 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| CN1255392C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管生成抑制剂的秋水仙醇衍生物 |
| TW200303304A (en) | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| US7009052B2 (en) | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
| GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| TWI332003B (en) | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| HRP20090250T1 (hr) | 2004-02-24 | 2009-06-30 | Japan Tobacco | Kondenzirani heterociklički spojevi i njihova upotreba kao inhibitora hcv polimeraze |
| NZ550534A (en) | 2004-03-25 | 2009-07-31 | Memory Pharm Corp | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| WO2007014226A2 (en) * | 2005-07-26 | 2007-02-01 | The Board Of Trustees Of The University Of Illinois | Compounds for the treatment of neurodegeneration and stroke |
| BRPI0706411A2 (pt) * | 2006-01-24 | 2011-03-29 | Lilly Co Eli | composto, composição farmacêutica, método de preparação de um indol ou um sal farmaceuticamente aceitável do mesmo, e, uso de um composto |
| JP2009530342A (ja) | 2006-03-20 | 2009-08-27 | エフ．ホフマン−ラ ロシュ アーゲー | Ｂｔｋおよびｓｙｋ蛋白キナーゼを阻害する方法 |
| EP2209775A1 (en) | 2007-10-09 | 2010-07-28 | UCB Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| WO2009051815A1 (en) | 2007-10-19 | 2009-04-23 | Bipar Sciences, Inc. | Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors |
| CN102089302A (zh) * | 2008-07-17 | 2011-06-08 | 旭化成制药株式会社 | 含氮二环性杂环化合物 |
| CN101429191B (zh) | 2008-11-03 | 2012-05-23 | 中国药科大学 | 取代的四氢异喹啉衍生物的用途 |
| JP2013517273A (ja) | 2010-01-13 | 2013-05-16 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 化合物および方法 |
| EP2566477B1 (en) | 2010-05-07 | 2015-09-02 | GlaxoSmithKline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
| US8846935B2 (en) * | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| US8946260B2 (en) | 2010-09-16 | 2015-02-03 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
| TW201307292A (zh) | 2010-12-17 | 2013-02-16 | Hoffmann La Roche | 經取代之６，６－稠合含氮雜環化合物及其用途 |
| EP2471363A1 (de) | 2010-12-30 | 2012-07-04 | Bayer CropScience AG | Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen |
| EP2714688B1 (en) | 2011-05-26 | 2016-02-24 | Daiichi Sankyo Company, Limited | Heterocyclic compounds as protein kinase inhibitors |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013067300A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
| CN105209031A (zh) | 2012-12-27 | 2015-12-30 | 德雷克塞尔大学 | 针对hbv感染的新型抗病毒剂 |
| CN105980365B (zh) | 2014-02-11 | 2019-06-21 | 拜耳医药股份公司 | 作为mIDH1抑制剂的苯并咪唑-2-胺 |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| MA41140A (fr) | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| AU2017360939B2 (en) | 2016-11-18 | 2022-03-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 |
| WO2020205646A2 (en) | 2019-03-29 | 2020-10-08 | Board Of Regents, The University Of Texas System | Small molecule parg inhibitors and methods of use thereof |
| KR20220066922A (ko) | 2019-09-20 | 2022-05-24 | 아이디어야 바이오사이언시스 인코포레이티드 | Parg 억제제로서 4-치환된 인돌 및 인다졸 설폰아미도 유도체 |
| AU2022359801A1 (en) | 2021-10-04 | 2024-02-01 | Forx Therapeutics Ag | Parg inhibitory compounds |
| AR128846A1 (es) | 2022-03-23 | 2024-06-19 | Ideaya Biosciences Inc | Compuestos de indazol sustituidos con piperazina como inhibidores de parg |
-
2015
- 2015-12-16 MA MA041179A patent/MA41179A/fr unknown
- 2015-12-17 EP EP15813554.1A patent/EP3233845B1/en active Active
- 2015-12-17 BR BR112017012707-5A patent/BR112017012707B1/pt active IP Right Grant
- 2015-12-17 CA CA2969298A patent/CA2969298C/en active Active
- 2015-12-17 RU RU2017125520A patent/RU2017125520A/ru not_active Application Discontinuation
- 2015-12-17 SG SG11201704843QA patent/SG11201704843QA/en unknown
- 2015-12-17 CN CN202110213641.5A patent/CN112979631B/zh active Active
- 2015-12-17 CN CN201580075709.0A patent/CN107295799B/zh active Active
- 2015-12-17 MX MX2017007976A patent/MX380901B/es unknown
- 2015-12-17 JP JP2017532912A patent/JP6673920B2/ja active Active
- 2015-12-17 WO PCT/GB2015/054064 patent/WO2016097749A1/en not_active Ceased
- 2015-12-17 US US15/533,819 patent/US10508086B2/en active Active
- 2015-12-17 EP EP21179871.5A patent/EP3907224A1/en active Pending
- 2015-12-17 KR KR1020177019869A patent/KR102682782B1/ko active Active
- 2015-12-17 AU AU2015365602A patent/AU2015365602B2/en active Active
- 2015-12-17 ES ES15813554T patent/ES2886471T3/es active Active
-
2017
- 2017-06-07 IL IL252745A patent/IL252745B/en active IP Right Grant
- 2017-06-28 ZA ZA2017/04383A patent/ZA201704383B/en unknown
-
2019
- 2019-10-24 US US16/662,997 patent/US10995073B2/en active Active
-
2021
- 2021-03-17 US US17/204,206 patent/US12129236B2/en active Active
-
2024
- 2024-09-19 US US18/889,613 patent/US20250223266A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | smyd inhibitors | |
| ZA201704383B (en) | Parg inhibitory compounds | |
| AP2017009836A0 (en) | Aminopyridyloxypyrazole compounds | |
| GB201411418D0 (en) | Compounds | |
| GB201415573D0 (en) | Compounds | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| GB201418300D0 (en) | Compounds | |
| GB201410430D0 (en) | Compounds | |
| GB201416186D0 (en) | Compounds | |
| GB201402431D0 (en) | Compounds | |
| GB201417561D0 (en) | Compounds | |
| GB201417369D0 (en) | Compounds | |
| GB201406591D0 (en) | Compounds | |
| GB201419264D0 (en) | Compounds | |
| GB201406956D0 (en) | Compounds | |
| GB201404987D0 (en) | Compounds | |
| GB201419228D0 (en) | Compounds | |
| GB201412660D0 (en) | Compounds | |
| AP2017009778A0 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| GB201417168D0 (en) | Compounds | |
| GB201419015D0 (en) | Compounds | |
| GB201407695D0 (en) | Compounds | |
| GB201405361D0 (en) | Compounds | |
| GB201607978D0 (en) | Inhibitory compounds | |
| GB201418154D0 (en) | Inhibitors |